← Eichor
Study identifier: NCT07527221 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Condition: Healthy Volunteers  ·  Sponsor: Eilean Therapeutics AU Pty Ltd

PhasePhase 1
Planned participants64
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersYes

About this study

This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.

This description comes directly from the study's public registry record.

Talk to the study team

Ekaterina Dokukina  ·  +1 858 353 4108  ·  kdokukina@eilenther.com

Always discuss trial participation with your own doctor first.

Locations (1)

Scientia Clinical Research Ltd.Randwick, New South Wales, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07527221